Close

Aquavit Pharmaceuticals Adds New Patent To Its High-Tech Medical Portfolio

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

2025 AI Trends & Pharma Predictions

As we navigate what the future of healthcare will...

Swiss Airtainer reaches major milestone with successful completion of first 50 commercial shipments

Swiss Airtainer is pleased to announce the successful completion of its first 50 commercial shipments of high-value life science...

Aquavit Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has issued a patent for Apollo Technology, System and Method for Personalized Injection Treatment.

This follows Aquavit’s European Patent issued by the European Patent Office (EPO) on July 27, 2016 and provides a global protection for the first of its kind smart compounding technology and its big data application.

Apollo Technology utilizes a revolutionary, integrated platform built into a desktop configuration that compounds customized formulations into a delivery tool of the user’s choice. This individualized assessment using big data platform analyzes specific needs and recommends personalized treatments.

This convenient form factor is linked with Aquavit’s patent pending “smart label” technology and accurately tracks supply chain and utilization with a built-in automated disposal system. The drug cartridges are equipped with security microchips and are prefilled with single injection dosage for compounding while digitally generating and recording the individual doses and formulations.

“The benefit of Apollo’s big data platform is that it offers a specialized interface between treatments and outcomes, where users are able to develop, implement, analyze and manage all data within a comprehensive operating system,” according to Dr. David Shafer, Double Board Certified Plastic Surgeon and Chief Medical Technology Officer of Aquavit.

Apollo would seek to benefit patients with specific needs and dosage requirements, especially effective for specialties that require various compounding techniques such as oncology and medical aesthetics. The broad applications of the smart technology can also be utilized in various consumer settings, including home-use and retail beauty counters. “The far-reaching potential of Aquavit’s technology is an exciting glimpse into the future of personalized treatment, management and medicine,” says Sobin Chang, Inventor of the Apollo System and Chief Executive Officer of Aquavit.

About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies.
For more information, visit www.aquavitpharma.com

Latest stories